A recent breakthrough in cancer immunotherapy reveals that β-hydroxybutyrate (BHB), a naturally occurring ketone body produced by the liver during prolonged fasting or ketogenic dieting, can dramatically enhance the metabolic fitness and antitumor potency of chimeric antigen receptor (CAR) T cells. This discovery, emerging from collaborative research conducted by scientists at the Arc Institute, Stanford University, and the University of Pennsylvania, introduces a novel metabolic angle to improving the efficacy of CAR T cell therapies—which, though revolutionary in treating certain hematologic malignancies, still face challenges including patient resistance and relapse.
CAR T cell therapy, a cutting-edge approach in immuno-oncology, involves engineering a patient’s own T cells to express receptors that specifically target cancer cells. Despite its success in blood cancers, many patients experience suboptimal responses or disease recurrence, underscoring the urgent need for strategies that augment T cell persistence and cytotoxicity without imposing additional treatment-related burdens. Maayan Levy, the study’s lead investigator and an Assistant Professor of Pathology at Stanford, approached this problem through a metabolic lens, hypothesizing that nutrient availability and energy substrate utilization might influence therapeutic outcomes.
The study meticulously evaluated the impact of diverse dietary regimens on CAR T cell function using murine cancer models. Diets ranging from high-fiber and Western-style to ketogenic were tested, revealing that only ketogenic feeding consistently improved tumor control when combined with CAR T therapy. This diet elevates circulating BHB levels, pinpointing the ketone body as a key modulator. To parse out whether direct BHB supplementation could recapitulate these benefits, the research team administered BHB alone, observing marked enhancements in CAR T cell expansion and tumor clearance—effects strikingly similar to the full ketogenic diet intervention.
Intriguingly, the BHB-mediated improvements depended strictly on the presence of engineered CAR T cells, as non-engineered T cells showed negligible response to BHB. Mechanistically, stable isotope metabolic tracing confirmed that CAR T cells actively metabolize BHB by incorporating it into the tricarboxylic acid (TCA) cycle, thus fueling mitochondrial respiration. Enhanced oxygen consumption rates and increased ATP production in BHB-treated CAR T cells validate this metabolic reprogramming, which bolsters the cells’ bioenergetic capacity and resilience against tumor-associated metabolic stress.
On a genomic level, single-cell transcriptomic profiling illuminated shifts induced by BHB exposure—CAR T cells upregulated genes associated with activation and cytotoxic function while downregulating exhaustion markers. Chromatin accessibility mapping using ATAC-seq and CUT&RUN further showed that BHB remodels the epigenetic landscape to favor regions linked to energy metabolism and immune effector pathways. These coordinated molecular changes underpin the enhanced antitumor efficacy observed in vivo.
To firmly establish that the therapeutic benefit hinges on metabolic consumption rather than a mere signaling effect of BHB, the investigators employed CRISPR gene editing to disrupt BDH1, the enzyme responsible for converting BHB into usable energy. Loss of BDH1 abrogated the BHB-induced enhancements in CAR T cells, underscoring the necessity of ketone metabolism for functional improvement.
This groundbreaking work not only underscores the untapped potential of metabolic interventions to extend the benefits of CAR T cell therapy but also offers a practically accessible adjunct approach. Ketogenic diets, while effective, present adherence challenges in cancer patients due to nutritional complexities and appetite disturbances. BHB supplementation circumvents these issues, potentially providing a safe, scalable, and cost-effective means to invigorate CAR T cells without genetic modification.
Looking ahead, a clinical trial assessing BHB supplementation in patients with Large B-cell Lymphoma is already underway, setting the stage for translation of these preclinical insights into clinical practice. The prospect of enhancing immunotherapy through metabolic support aligns with a growing recognition that cancer treatment requires multidimensional strategies—integrating genetics, immune modulation, and now bioenergetic optimization—to surmount tumor immune evasion.
Levy’s team exemplifies how dissecting the metabolic underpinnings of immune cell function can open novel avenues for therapy, particularly when genetic engineering approaches reach their limitations. Their findings advocate for leveraging innate cellular biochemistry via ketone bodies to reinforce T cell vitality and function, enhancing durable cancer control in resistant and difficult-to-treat malignancies like pancreatic cancer.
This study represents a paradigm shift, suggesting that simple, natural metabolites—far from passive bystanders—play active roles in shaping immune cell performance. As the field moves toward more sophisticated and patient-friendly immunotherapies, integrating metabolic supplementation could redefine standard of care, offering renewed hope to patients battling relapsed or refractory cancers.
The convergence of immunology, metabolism, and oncology embodied in this work is emblematic of a broader scientific renaissance that recognizes the interdependence of biological systems. Metabolic reprogramming in CAR T cells, harnessed through endogenous molecules like BHB, points to a revolutionary yet elegantly natural tactic to amplify immunotherapy’s reach and efficacy.
In summary, this landmark research elevates β-hydroxybutyrate from a mere metabolic byproduct to a central player in bolstering CAR T cell metabolism and function. The clinical implications are profound, promising a future in which metabolic interventions enhance the power of cellular therapies, potentially transforming outcomes across a spectrum of challenging cancers.
Subject of Research: Animals
Article Title: β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer
News Publication Date: 6-Mar-2026
Web References:
https://doi.org/10.1016/j.cell.2026.02.004
References:
Liu, S., Guruprasad, P., Ramasubramanian, R., Madhu, B., Paruzzo, L., Han, K., Kelly, A., Shestov, A., Xu, H.N., Carturan, A., Zhou, C., Amses, K.R., Afriat, A., Litichevskiy, L., Lin, J., Dubowitz, E., Tangal, N., Zhang, J., McSween, A., Tan, M., Stella, F., Lee, A., Nason, S., Hua, X., Schneider, M., Sleeman, M., Zhang, Y., Gabrielli, G., Yang, Z., Pajarillo, R., Patel, R., Ghilardi, G., Patel, V., Joshi, A., Jiang, S., Jiang, Y., Porazzi, P., Tchou, J.C., Keith, B., Li, M., Chong, E., Schuster, S.J., Milone, M., Rabinowitz, J., O’Connor, R., Thaiss, C.A., Levy, M., & Ruella, M. (2026). β-Hydroxybutyrate Enhances the Metabolic Fitness of CAR T Cells in Cancer. Cell. https://doi.org/10.1016/j.cell.2026.02.004
Image Credits: Arc Institute
Keywords: Metabolites, Immunotherapy
Tags: CAR T cell therapy in hematologic malignanciesenergy substrates in T cell functionhuman clinical trials of ketone supplementsimproving CAR T cell persistenceketogenic diet and cancer treatmentketone supplementation in cancer therapymetabolic enhancement of immunotherapymetabolic fitness of T cellsnutrient availability and cancer immunotherapyovercoming resistance in immunotherapypreclinical mouse models for cancer immunotherapyβ-hydroxybutyrate effects on CAR T cells
